Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Peds Proton Therapy

13 de novembro de 2026 atualizado por: University of Wisconsin, Madison

Operational and Clinical Evaluation of the Treatment Planning Software and Oncology Information System for Pediatric Proton Therapy

This study is being done to evaluate the clinical utilization and safety of RayStation 2025 and RayCare 2025 treatment planning software upgrades when used to support standard-of-care proton therapy delivery in patients deemed clinically appropriate for such therapy by their treating radiation oncologist.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

In this study, the radiation treatment itself, including target definitions, prescription dose, treatment delivery, verification imaging, and adaptive treatment planning, is standard of care.

Current standard radiation therapy planning is based on a treatment plan generated from a planning computed tomography (CT) scan obtained before treatment begins. This plan is generally used for the entire course of therapy, with verification imaging performed during treatment primarily used to verify patient positioning rather than to recalculate delivered dose. On occasion, it is standard practice for a physician to determine, based on his or her interpretation of verification imaging, that an adaptive replanning of the treatment is needed to account for anatomic changes that the physician observes on verification imaging which mandate a change to the plan. Comprehensive software-based evaluation of the cumulative dose delivered over multiple fractions is not routinely performed in most clinical settings. Performing such evaluations typically requires manual steps including image registration, dose recalculation on additional imaging datasets, deformable dose mapping, and manual accumulation of dose across fractions. With currently FDA-approved tools for proton therapy treatment plan evaluation, these processes are time-consuming and require significant physics and physician resources. As a result, detailed adaptive dose evaluation is usually performed only in selected cases or as a one-time assessment during a treatment course, rather than as a routine component of daily clinical care.

The investigational component involves the prospective evaluation of the RayAdaptive and RayTracker software tools to assess their performance, reliability, usability, and clinical feasibility. These software features are not currently available for routine clinical use, being not yet FDA-cleared, in the configuration evaluated in this protocol and are being assessed in a defined prospective clinical research setting.

This is a nonrandomized, single arm, open-label, prospective interventional trial to determine the rate of adaptive replanning for proton therapy when RayTracker and RayAdaptive are used as decision-support tools in the analysis of every verification image obtained during each participant's proton therapy treatment course. This study will evaluate, under a defined prospective clinical research framework, the performance, reliability, usability, and clinical feasibility of implementing RayTracker and RayAdaptive - software components that have not yet been 510(k) cleared by the U.S. Food and Drug Administration (FDA).

Primary Objective

• To determine the frequency of adaptive replanning during proton therapy when RayTracker and RayAdaptive are incorporated into routine verification image review as clinical decision-support tools.

Secondary Objectives

  • To evaluate the treating physician-reported rate at which RayTracker and RayAdaptive influenced the decision to pursue adaptive replanning during proton therapy.
  • To explore concordance between RayAdaptive-predicted inadequate target coverage on verification imaging and findings on repeat CT simulation when performed.
  • To explore concordance between RayAdaptive-predicted organ-at-risk dose constraint violations and findings on repeat CT simulation when performed.
  • To report the incidence of adverse events (AEs) and device deficiencies related to the investigational RayTracker/RayAdaptive software.

Tipo de estudo

Intervencional

Inscrição (Estimado)

80

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Wisconsin
      • Madison, Wisconsin, Estados Unidos, 53792
        • Recrutamento
        • University of Wisconsin

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

Não mais velho que 17 anos (Filho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Age less than or equal to 17 years at the time of consent/assent.
  • Patient has a clinical indication for radiation therapy, and the treating radiation oncologist has independently determined that proton therapy is clinically appropriate and has recommended proton therapy as part of the patient's routine clinical care, independent of participation in this research study. Proton therapy may be delivered with or without anesthesia when clinically indicated.
  • Written informed consent will be obtained from adult subjects or the parent/legal guardian of pediatric subjects. Assent will be obtained from pediatric participants when appropriate according to institutional policy.

Exclusion Criteria:

  • Patient has contraindications to proton therapy (per standard clinical guidelines).
  • Patient is unable to comply with routine treatment workflow or follow-up.
  • Patients who will be treated with a radiation plan of 5 fractions or fewer.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Standard of Care Proton Therapy

Part of a not yet FDA-cleared software, the RaySearch treatment planning system and RayCare oncology information system. RayTracker enables longitudinal evaluation of treatment by recalculating dose on daily images and accumulating dose across fractions using deformable image registration, thereby providing an estimate of the cumulative delivered dose to targets and organs at risk. RayAdaptive uses daily treatment imaging (such as cone-beam CT (CBCT)) together with the planning CT to generate an updated representation of patient anatomy and recalculation of dose on the current patient anatomy, allowing clinicians to evaluate whether anatomical changes could meaningfully alter the planned dose distribution. These features are designed to be used in tandem. Their combined capabilities are intended to support clinical decision-making related to treatment monitoring and potential adaptation.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Proportion of verification image assessments for each subject resulting in a clinical adaptive replanning decision
Prazo: up to 6 months

Defined as ordering repeat CT simulation and/or treatment plan reoptimization.

up to 6 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Treating physician-reported influence of RayTracker/RayAdaptive on adaptive replanning decisions
Prazo: up to 6 months

Can I define this outcome to be: Did the RayTracker / RayAdaptive intervention influence your clinical decision? [Yes / No] This will be reported by physician count.

up to 6 months
Concordance between RayAdaptive predictions of inadequate target coverage and findings on repeat CT simulation
Prazo: up to 6 months
up to 6 months
Concordance between RayAdaptive predictions of organ-at-risk dose constraint violations and findings on repeat CT simulation
Prazo: up to 6 months
up to 6 months
Incidence of AEs and device deficiencies
Prazo: up to 6 months

Incidence of AEs and device deficiencies at least possibly related to use of the investigational RayTracker/RayAdaptive software or its incorporation into the clinical workflow as assessed throughout the course of proton therapy and for 90 days following completion of proton treatment. Device deficiencies may include software malfunction, calculation error, deformable registration failure, software defect, or software limitations affecting treatment plan evaluation, image review, or data analysis.

up to 6 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Brett Morris, MD, PhD, UW School of Medicine and Public Health

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

13 de outubro de 2026

Conclusão Primária (Estimado)

1 de janeiro de 2029

Conclusão do estudo (Estimado)

1 de janeiro de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

13 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

13 de novembro de 2026

Primeira postagem (Real)

19 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

19 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

13 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 2026-1312
  • Protocol Version 7/26/26 (Outro identificador: UW Madison)
  • SMPH | Radiation Medicine (Outro identificador: UW Madison)
  • UW26111 (Outro identificador: OnCore ID)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Sim

produto fabricado e exportado dos EUA

Sim

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .